These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 1303818)
21. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer. Oehler MK; Sütterlin M; Caffier H Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185 [TBL] [Abstract][Full Text] [Related]
22. Clinical evaluation of tumor-associated mucin-type glycoprotein CA 54/61 in ovarian cancers: comparison with CA 125. Suzuki M; Sekiguchi I; Tamada T Obstet Gynecol; 1990 Sep; 76(3 Pt 1):422-7. PubMed ID: 2381620 [TBL] [Abstract][Full Text] [Related]
23. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary. Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350 [TBL] [Abstract][Full Text] [Related]
24. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer. Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265 [TBL] [Abstract][Full Text] [Related]
25. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer. Eskelinen M; Tikanoja S; Brown J Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995 [TBL] [Abstract][Full Text] [Related]
26. [Relationship between tumor markers and clinical symptoms in ovarian cancer]. Yakushiji M; Nishimura H Rinsho Byori; 1992 Apr; 40(4):354-8. PubMed ID: 1593760 [TBL] [Abstract][Full Text] [Related]
27. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions. Gaspar MJ; De Miguel J; García Díaz JD; Díez M Anticancer Res; 2008; 28(5B):2947-52. PubMed ID: 19031938 [TBL] [Abstract][Full Text] [Related]
28. [Tumor markers in epithelial ovarian cancer]. Di Cocco B; Calabretta F; Alghisi F; Salesi N; Bossone G Minerva Ginecol; 2003 Aug; 55(4):327-32. PubMed ID: 14581857 [TBL] [Abstract][Full Text] [Related]
29. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer]. Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018 [TBL] [Abstract][Full Text] [Related]
30. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study. Sehouli J; Akdogan Z; Heinze T; Könsgen D; Stengel D; Mustea A; Lichtenegger W Anticancer Res; 2003; 23(2A):1115-8. PubMed ID: 12820357 [TBL] [Abstract][Full Text] [Related]
31. [Studies of clinical usefulness of new tumor markers of ovarian cancer, CA 54/61 and CA 602--CA 602 assay reagent kit, performance its normal value and correlations with other tumor markers]. Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M Gan To Kagaku Ryoho; 1992 Oct; 19(12):2085-93. PubMed ID: 1417016 [TBL] [Abstract][Full Text] [Related]
32. Clinical evaluation of a new tumour marker TAG 12 in breast cancer. Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P Anticancer Res; 1991; 11(2):805-8. PubMed ID: 2064336 [TBL] [Abstract][Full Text] [Related]
33. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer. Koelbl H; Schieder K; Neunteufel W; Bieglmayer C Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933 [TBL] [Abstract][Full Text] [Related]
34. Clinical value of squamous cell carcinoma antigen (SCC-A) in Egyptian gynecologic cancer patients. Salman T; el-Ahmady O; Tony O; Darwish M Anticancer Res; 1997; 17(4B):3083-6. PubMed ID: 9329607 [TBL] [Abstract][Full Text] [Related]
35. TAG-72 expression and its role in the biological evaluation of human colorectal cancer. Guadagni F; Roselli M; Cosimelli M; Ferroni P; Spila A; Cavaliere F; Arcuri R; Carlini S; Mariotti S; Gandolfo GM; Casciani CU; Greiner JW; Schlom J Anticancer Res; 1996; 16(4B):2141-8. PubMed ID: 8694534 [TBL] [Abstract][Full Text] [Related]
36. [MSA--a new sensitive tumor marker in breast carcinoma]. Zahm DM; Greinke C; Nöschel H Zentralbl Gynakol; 1996; 118(12):659-64. PubMed ID: 9082702 [TBL] [Abstract][Full Text] [Related]
37. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients]. Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923 [TBL] [Abstract][Full Text] [Related]
38. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer. Peters-Engl C; Medl M; Ogris E; Leodolter S Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Chen DX; Schwartz PE; Li XG; Yang Z Obstet Gynecol; 1988 Jul; 72(1):23-7. PubMed ID: 3164105 [TBL] [Abstract][Full Text] [Related]
40. [Study on serum vascular endothelial growth factor level in ovarian malignant tumors]. Li L; Wang LM; Zhang W; Zhang JQ; Song HL; Yao DS; Tang Y; Chen XQ; Yang ZH Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):72-6. PubMed ID: 12783691 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]